Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 2.4t

Novo Nordisk Balance Sheet Health

Financial Health criteria checks 3/6

Novo Nordisk has a total shareholder equity of DKK143.5B and total debt of DKK96.0B, which brings its debt-to-equity ratio to 66.9%. Its total assets and total liabilities are DKK465.8B and DKK322.3B respectively. Novo Nordisk's EBIT is DKK139.9B making its interest coverage ratio -706.5. It has cash and short-term investments of DKK26.3B.

Key information

66.9%

Debt to equity ratio

DKK 96.02b

Debt

Interest coverage ratio-706.5x
CashDKK 26.31b
EquityDKK 143.49b
Total liabilitiesDKK 322.31b
Total assetsDKK 465.80b

Recent financial health updates

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Recent updates

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 28
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28
The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Financial Position Analysis

Short Term Liabilities: NOVO B's short term assets (DKK160.9B) do not cover its short term liabilities (DKK217.5B).

Long Term Liabilities: NOVO B's short term assets (DKK160.9B) exceed its long term liabilities (DKK104.8B).

Debt to Equity History and Analysis

Debt Level: NOVO B's net debt to equity ratio (48.6%) is considered high.

Reducing Debt: NOVO B's debt to equity ratio has increased from 1.1% to 66.9% over the past 5 years.

Debt Coverage: NOVO B's debt is well covered by operating cash flow (126%).

Interest Coverage: NOVO B earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/10 00:10
End of Day Share Price 2025/03/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 68 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research